UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases

Journal of clinical oncology, 2006-05, Vol.24 (13), p.2065-2072

2006

Volltextzugriff (PDF)

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2505-2512

2006

Volltextzugriff (PDF)

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

Annals of surgical oncology, 2006-08, Vol.13 (8), p.1035-1046

2006

Volltextzugriff (PDF)

Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial

Journal of clinical oncology, 2004-07, Vol.22 (13), p.2610-2616

2004

Volltextzugriff (PDF)

Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity

Cancer research (Chicago, Ill.), 2004-03, Vol.64 (6), p.2030-2038

2004

Volltextzugriff (PDF)

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis

Oncogene, 2003-01, Vol.22 (3), p.319-329

2003

Volltextzugriff (PDF)

Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer

Journal of clinical oncology, 2006-03, Vol.24 (7), p.1145-1151

2006

Volltextzugriff (PDF)

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

The oncologist (Dayton, Ohio), 2017-12, Vol.22 (12), p.1427-e129

2017

Volltextzugriff (PDF)

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer

Cancer, 2008-10, Vol.113 (8), p.2046-2052

2008

Volltextzugriff (PDF)

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer

Investigational new drugs, 2018-10, Vol.36 (5), p.895-902

2018

Volltextzugriff (PDF)

Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668

Clinical cancer research, 2005-01, Vol.11 (2), p.678-689

2005

Volltextzugriff (PDF)

Molecular targeting therapy for pancreatic cancer

Cancer chemotherapy and pharmacology, 2004-09, Vol.54, p.S69-S77

XIONG, Henry Q

2004

Volltextzugriff (PDF)

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

Seminars in oncology, 2002-10, Vol.29 (5), p.31-37

2002

Volltextzugriff (PDF)

NF‐κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells

International journal of cancer, 2004-01, Vol.108 (2), p.181-188

2004

Volltextzugriff (PDF)

Cytotoxic Chemotherapy for Pancreatic Cancer : Advances to Date and Future Directions

Drugs (New York, N.Y.), 2006-01, Vol.66 (8), p.1059-1072

2006

Volltextzugriff (PDF)

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines

Cancer research (Chicago, Ill.), 2006-04, Vol.66 (7), p.3802-3812

2006

Volltextzugriff (PDF)

Phase I and Pharmacological Study of Oral 9-Aminocamptothecin Colloidal Dispersion (NSC 603071) in Patients with Advanced Solid Tumors

Clinical cancer research, 2003-06, Vol.9 (6), p.2066-2071

2003

Volltextzugriff (PDF)

A phase I surrogate endpoint study of SU6668 in patients with solid tumors

Investigational new drugs, 2004-11, Vol.22 (4), p.459-466

2004

Volltextzugriff (PDF)

Report of the 16th International Symposium of the Foundation for Promotion of Cancer Research: Recent Advances in Pancreatic Cancer

Japanese journal of clinical oncology, 2003-05, Vol.33 (5), p.246-253

2003

Volltextzugriff (PDF)

Prostaglandin E2 drives cyclooxygenase 2 expression via cyclic AMP response element activation in human pancreatic cancer cells

Cancer biology & therapy, 2005-11, Vol.4 (11), p.1263-1269

2005

Volltextzugriff (PDF)

Chemoradiation for resectable gastric cancer

The lancet oncology, 2003-08, Vol.4 (8), p.498-505

2003

Volltextzugriff (PDF)

Treatment of colorectal cancer metastasis: the role of chemotherapy

Cancer and metastasis reviews, 2004-01, Vol.23 (1-2), p.145-163

2004

Volltextzugriff (PDF)

A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer

Cancer chemotherapy and pharmacology, 2005-06, Vol.55 (6), p.559-564

2005

Volltextzugriff (PDF)

Novel therapies for pancreatic adenocarcinoma

Current oncology reports, 2004-06, Vol.6 (3), p.199-206

2004

Volltextzugriff (PDF)

A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.365-365

2020

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(53)
Buchkapitel
(2)

Sprache

Englisch
(55)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(31)
Science & Technology
(31)
Life Sciences & Biomedicine
(28)
Oncology
(20)
Biological And Medical Sciences
(19)
Female
(17)
Medical Sciences
(17)
Male
(16)
Pancreatic Neoplasms - Pathology
(15)
Pancreatic Neoplasms - Drug Therapy
(14)
Aged
(13)
Middle Aged
(13)
Tumors
(13)
Adult
(12)
Animals
(12)
Pancreatic Cancer
(12)
Deoxycytidine - Analogs & Derivatives
(9)
Gastroenterology. Liver. Pancreas. Abdomen
(9)
Pharmacology & Pharmacy
(8)
Treatment Outcome
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial

Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis

Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer

Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668

Molecular targeting therapy for pancreatic cancer

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

NF‐κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells

Cytotoxic Chemotherapy for Pancreatic Cancer : Advances to Date and Future Directions

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines

Phase I and Pharmacological Study of Oral 9-Aminocamptothecin Colloidal Dispersion (NSC 603071) in Patients with Advanced Solid Tumors

A phase I surrogate endpoint study of SU6668 in patients with solid tumors

Report of the 16th International Symposium of the Foundation for Promotion of Cancer Research: Recent Advances in Pancreatic Cancer

Prostaglandin E2 drives cyclooxygenase 2 expression via cyclic AMP response element activation in human pancreatic cancer cells

Chemoradiation for resectable gastric cancer

Treatment of colorectal cancer metastasis: the role of chemotherapy

A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer

Novel therapies for pancreatic adenocarcinoma

A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer

Suchergebnisse filtern